Here are the 8-K filings from Armada Acquisition Corp. III (AACI) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An 8-K covers material events a company has to report between its quarterly reports, so if you follow AACI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AACI filings page.
Armada Acquisition Corp. III (AACI) entered into a definitive agreement for a proposed business combination with Brains Bioceutical Corp. and Brains Therapeutics Corp. The agreement sets Brains’ enterprise value at $750.0 million; consideration to Brains security holders consists of PubCo shares, rollover equity awards and warrants, based on transaction value after specified balance-sheet and expense adjustments, divided by a $10.20 per-share reference value.
The agreement provides for 14,705,882 additional PubCo earnout shares, held in escrow, with half released at each of two price milestones: $12.50 and $15.00 per share. Each requires a volume-weighted average price at or above the threshold for at least 20 trading days within any consecutive 30-trading-day period. The earnout period starts six months after closing and ends three years after closing; shares without a triggering event are forfeited and cancelled.
The parties will use commercially reasonable efforts to enter transaction financings with aggregate proceeds of up to $100.0 million. Closing is expected in the second quarter of 2027, subject to approvals and other conditions, including PubCo having at least $5,000,001 in consolidated net tangible assets immediately after the transactions. Either Armada or Brains may terminate if closing has not occurred by June 30, 2027, subject to contractual exceptions.